I was immediately thinking that they may just want to take advantage of the somewhat extraordinary success GSK just had. They really exceeded expectations, then dropped a share buyback on top like a cherry. It may be that Citadel sees this being an untenable price for the company. It’s rare for any stock to just keep surging forward month after month, quarter after quarter.

But it is a publicly gigantic amount they’re investing. If they do know something it logically falls into two options. The worry over vaccines and overall pharma valuations as the new administration decides to just detail the train to stop it instead of easing it to a rail yard for inspection. Or, the idea that the need for acquisitions to bolster their portfolio means that the price will take a hit. Traditionally the acquiring company loses share price while the smaller company makes the big gains. Whether that’s something involving Cytodyn will play out, but as a general rule that tends to happen with any big deal.